Gamida Set For Breakthrough Transplant Therapy Approval – But Cash Problems Could Hit Launch

Can Gamida Succeed On Its Own?

 
• By Andrew McConaghie
  
Stem cell
Gamida Cell believes its therapy can show superior efficacy and healthcare cost savings - but the company cash shortage is a concern. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip